Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Although fibrosis is becoming increasingly recognized as a major cause of morbidity and mortality in modern societies, targeted anti fibrotic therapies are still not approved for most fibrotic disorders.However, intense research over the last decade has improved our understanding of the underlying pathogenesis of fibrotic diseases.We now appreciate fibrosis as the consequence of a persistent tissue repair responses, which, in contrast to normal wound healing, fails to be effectively terminated.Profibrotic mediators released from infiltrating leukocytes, activated endothelial cells and degranulated platelets may predominantly drive fibroblast activation and collagen release in early stages, whereas endogenous activation of fibroblasts due epigenetic modifications and biomechanical or physical factors such as stiffening of the extracellular matrix and hypoxia may play pivotal role for disease progression in later stages.In the present review, we discuss novel insights into the pathogenesis of fibrotic diseases using systemic sclerosis (SSc) as example for an idiopathic, multisystem disorder.We set a strong translational focus and predominantly discuss approaches with very high potential for rapid transfer from bench to bedside.We highlight the molecular basis for ongoing clinical trials in SSc and also provide an outlook on upcoming trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541 · cited 1×
“diseases may thus be considered to be exaggerated and prolonged wound-healing responses (1).”
BackgroundMunger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683 · cited 1×
“statin, a protein known for its antiangiogenic activity (80).”
BackgroundBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
Barry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H. M., Oyasu, M., Mikels, A., Vaysberg, M., Ghermazien, H., Wai, C., et al. (2010) · Nature Medicine · doi:10.1038/nm.2208 · Cited by 870
Henderson, N. C., Arnold, T. D., Katamura, Y., Giacomini, M. M., Rodriguez, J. D., McCarty, J. H., Pellicoro, A., Raschperger, E., Betsholtz, C., Ruminski, P. G., et al. (2013) · Nature Medicine · doi:10.1038/nm.3282 · Cited by 866
NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury
Hecker, L., Vittal, R., Jones, T., Jagirdar, R., Luckhardt, T. R., Horowitz, J. C., Pennathur, S., Martinez, F. J., & Thannickal, V. J. (2009) · Nature Medicine · doi:10.1038/nm.2005 · Cited by 852 · cited 1×
“Both a deficiency of NOX-4 and inhibition of NOX-4 by targeting with a small molecule (GKT137831) have been shown to reduce fibroblast activation in the lung and liver (69,70).”
BackgroundReversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance
Hecker, L., Logsdon, N. J., Kurundkar, D., Kurundkar, A., Bernard, K., Hock, T., Meldrum, E., Sanders, Y. Y., & Thannickal, V. J. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008182 · Cited by 686 · cited 1×
“Both a deficiency of NOX-4 and inhibition of NOX-4 by targeting with a small molecule (GKT137831) have been shown to reduce fibroblast activation in the lung and liver (69,70).”
BackgroundA vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response
Ding, N., Yu, R. T., Subramaniam, N., Sherman, M. H., Wilson, C., Rao, R., Leblanc, M., Coulter, S., He, M., Scott, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.028 · Cited by 622
Chiaramonte, M. G., Donaldson, D. D., Cheever, A. W., & Wynn, T. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7325 · Cited by 603 · cited 1×
“IL-13–targeting therapies were shown to attenuate experimental pulmonary and hepatic fibrosis (31,32).”
BackgroundInterleukin-33-Dependent Innate Lymphoid Cells Mediate Hepatic Fibrosis
Mchedlidze, T., Waldner, M., Zopf, S., Walker, J., Rankin, A. L., Schuchmann, M., Voehringer, D., McKenzie, A. N. J., Neurath, M. F., Pflanz, S., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.018 · Cited by 502
Denton (2007) · doi:10.1002/art.22289 · Cited by 447
Rice, L. M., Padilla, C. M., McLaughlin, S. R., Mathes, A., Ziemek, J., Goummih, S., Nakerakanti, S., York, M., Farina, G., Whitfield, M. L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77958 · Cited by 351
The α v β 1 integrin plays a critical in vivo role in tissue fibrosis
Reed, N. I., Jo, H., Chen, C., Tsujino, K., Arnold, T. D., DeGrado, W. F., & Sheppard, D. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5094 · Cited by 311
Distler, O., Distler, J. H. W., Scheid, A., Acker, T., Hirth, A., Rethage, J., Michel, B. A., Gay, R. E., Müller-Ladner, U., Matucci-Cerinic, M., et al. (2004) · Circulation Research · doi:10.1161/01.res.0000134644.89917.96 · Cited by 310
Self-citationPlatelet-derived serotonin links vascular disease and tissue fibrosis
Dees, C., Akhmetshina, A., Zerr, P., Reich, N., Palumbo, K., Horn, A., Jüngel, A., Beyer, C., Krönke, G., Zwerina, J., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101629 · Cited by 266 · cited 2×
“Mice deficient in 5-HT2B are protected from the development of experimental skin fibrosis (7).”
BackgroundSelf-citationIncreased PDGFRα Activation Disrupts Connective Tissue Development and Drives Systemic Fibrosis
Olson, L. E., & Soriano, P. (2009) · Developmental Cell · doi:10.1016/j.devcel.2008.12.003 · Cited by 264
Stimulating healthy tissue regeneration by targeting the 5-HT2B receptor in chronic liver disease
Ebrahimkhani, M. R., Oakley, F., Murphy, L. B., Mann, J., Moles, A., Perugorria, M. J., Ellis, E., Lakey, A. F., Burt, A. D., Douglass, A., et al. (2011) · Nature Medicine · doi:10.1038/nm.2490 · Cited by 221
Huang, J., Beyer, C., Palumbo-Zerr, K., Zhang, Y., Ramming, A., Distler, A., Gelse, K., Distler, O., Schett, G., Wollin, L., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207109 · Cited by 196 · cited 1×
“tured fibroblasts and showed antifibrotic effects in various in vivo models of SSc (105).”
BackgroundSelf-citationIntegrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma
Gerber, E. E., Gallo, E. M., Fontana, S. C., Davis, E. C., Wigley, F. M., Huso, D. L., & Dietz, H. C. (2013) · Nature · doi:10.1038/nature12614 · Cited by 190
Cited by
Yang (2021) · doi:10.1038/s41598-020-79139-8 · Cited by 5,035
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Self-citationTargeting TGF-β signaling for the treatment of fibrosis
Györfi, A. H., Matei, A.-E., & Distler, J. H. W. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.016 · Cited by 274
Self-citationTGF-β as A Master Regulator of Aging-Associated Tissue Fibrosis
Ren, L.-L., Miao, H., Wang, Y.-N., Liu, F., Li, P., & Zhao, Y.-Y. (2023) · Aging and disease · doi:10.14336/ad.2023.0222 · Cited by 139
Bagnato, G. L., Irrera, N., Pizzino, G., Santoro, D., Roberts, W. N., Bagnato, G., Pallio, G., Vaccaro, M., Squadrito, F., Saitta, A., et al. (2018) · Clinical Science · doi:10.1042/cs20171426 · Cited by 51
Metadata
- Authors
- Distler, J. H. W., Feghali‐Bostwick, C., Soare, A., Asano, Y., Distler, O., & Abraham, D. J.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2017-01-28
- Volume
- 69
- Issue
- 2
- Pages
- 257-267
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2519768493
- Cited by
- 82
- References
- 21
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.